Oaktree Capital Management »

Alnylam Pharmaceuticals Inc Note 1.000 9/1 shares owned by Oaktree Capital Management

Quarter-by-quarter ownership of Alnylam Pharmaceuticals Inc Note 1.000 9/1 shares owned by Oaktree Capital Management from 13F filings

Historical chart of Oaktree Capital Management investment in Alnylam Pharmaceuticals Inc Note 1.000 9/1

Tip: Access up to 7 years of quarterly data

All positions including Alnylam Pharmaceuticals Inc Note 1.000 9/1 held by Oaktree Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alnylam Pharmaceuticals Inc Note 1.000 9/1 by Oaktree Capital Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $2.1M 1.8M 1.17
2024-03-31 $2.8M 2.9M 0.94
2023-12-31 $2.5M 2.5M 0.99
2023-09-30 $2.3M 2.5M 0.93

More positions owned by Oaktree Capital Management

Torm Common Stock (TRMD)
Chesapeake Energy Corp Common Stock (CHK)
Garrett Motion Common Stock (GTX)
Sitio Royalties Corp Common Stock (STR)
State Street Corp Etf Put Option (SPY)
Infinera Corp Common Stock (INFN)
Anglogold Ashanti Common Stock (AU)
Liberty Global Common Stock Call Option (LBTYA)
Star Bulk Carriers Corp Common Stock (SBLK)
Sunopta Common Stock (STKL)
Talen Energy Corp Common Stock (TLN)
Freeport-mcmoran Common Stock (FCX)
Runway Growth Finance Corp Common Stock (RWAY)
Vista Energy Sab De Cv Common Stock (VIST)
California Resources Corp Common Stock (CRC)

View all positions for Oaktree Capital Management

Top funds holding Alnylam Pharmaceuticals Inc Note 1.000 9/1

Ing Investment Management
Deerfield Management Company
Aequim Alternative Investments
Lazard Asset Management
BlackRock
Davidson Kempner Capital Management
Calamos Advisors
Invesco
BlackRock
State Street Corporation
Morgan Stanley
MacKay Shields
Shenkman Capital Management
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
Capstone Investment Advisors

View all funds holding Alnylam Pharmaceuticals Inc Note 1.000 9/1